The mainstay of treatment for type 1 diabetes (T1D) is exogenous insulin. Here, we report a case in which exogenous insulin requirements were eliminated after an allogeneic hematopoietic stem cell transplant for aplastic anemia in a pediatric patient recently diagnosed with T1D, and explore the validity of this approach compared with current treatments. Testing for Fanconi anemia and paroxysmal nocturnal hemoglobinuria were negative. Hemoglobin A1c (HbA1c) was 7.8%. Three of the four pancreatic antibodies associated with T1D were positive ( Table 1) .
| INTRODUCTION
Type 1 diabetes (T1D) is a chronic autoimmune disease in which pancreatic β-cell destruction results in loss of endogenous insulin production. Already one of the most prevalent chronic childhood diseases, the incidence of T1D in children and young adults is projected to continue to increase over the next several decades. 1 Although advances in technology have allowed for improved glucose monitoring and insulin delivery, no curative therapy is currently available for this growing patient population. Moreover, patients continue to experience long-term complications such as blindness and kidney failure, even with the most intensive insulin regimens. 2 Consequently, the direct and indirect medical costs of this disease are substantial. When considering the 1.1 million patients with T1D identified in 2005, the estimated lifetime direct medical cost and cost due to lost income are $133.7 and $289 billion, respectively. 3 
| CASE REPORT
A previously healthy 17-year-old male presented to his primary care physician with an 8-day history of petechiae, epistaxis and frank hematuria. Past medical and social histories were noncontributory. Testing for Fanconi anemia and paroxysmal nocturnal hemoglobinuria were negative. Hemoglobin A1c (HbA1c) was 7.8%. Three of the four pancreatic antibodies associated with T1D were positive ( Table 1 ).
The patient was diagnosed with idiopathic aplastic anemia and T1D.
Primary treatment of the aplastic anemia was allogeneic hematopoi- 
| DISCUSSION
To our knowledge, the question of whether HSCT from a matched sibling donor could be considered as a curative treatment option for children with early onset T1D has not been formally studied. Virtually all research on the role of HSCT for T1D has focused on autologous transplantation, and many questions remain unanswered.
Autologous HSCT utilizes immunosuppression in the form of pretransplant lymphoablative chemotherapy to reset the immune system.
The patient's own stem cells are then infused to facilitate hematopoietic recovery and generate a naïve, and more tolerant, immune system.
Resolution of an autoimmune condition with immunosuppression is not a new phenomenon. However, whether sustained remission of the condition can be achieved once the immunosuppression has been withdrawn is a key question in studies evaluating the role of autologous HSCT to treat autoimmune disease. 4 Results from studies investigating this approach for T1D have been varied. In one study from Brazil, autologous HSCT was used to treat new onset T1D and resulted in a cessation of insulin therapy for a mean of 40 months in 9 of 22 patients, with reduction of HbA1c and variable increases in cpeptide levels during time of follow up. 5, 6 In contrast, a Chinese pediatric study comparing autologous HSCT recipients with matched standard insulin treatment controls found similarly elevated HbA1c levels, and no significant difference in c-peptide or insulin dose requirements between groups at 1-, 3-, and 5-year follow up. When using an HLA-matched allogeneic donor to treat an autoimmune condition, there is an additional concern that the intolerant immune system will redevelop post-transplant. Specific combinations at the DQA1, DQB1, and DRB1 HLA loci (e.g. DR3, DR4) determine the extent of haplotypic risk of T1D, although HLA is not the only predictor of risk. 13 Notably, the patient and donor presented in this case report carried no high-risk loci. However, identically matching HLA haplotypes that do confer risk in order to optimize transplant outcomes may contribute to the risk for the return of autoimmunity. This concern may be lessened by proactively identifying other markers of T1D risk. The presence of islet autoantibodies (GAD-65, IA-2, ZnT8), and islet cell antibodies in relatives of patients with diabetes has been shown to be a risk factor for the development of TID. 14 One study revealed that in a group of high-risk HLA-typed siblings of T1D patients, 70% of those with positive islet cell antibodies went on to develop T1D by 8 years of follow up, compared to only 5% of siblings with negative islet cell antibodies. 15 Thus, the identification of pancreatic autoantibodies (e.g. islet cell antibodies) could be a valuable screening tool in unaffected HLA identical siblings to reduce the risk of post-transplant disease recurrence.
| CONCLUSION
Given the rising costs and burden of T1D, continued investigation for innovative treatments is a timely and worthwhile pursuit. This case illustrates the curative potential for allogeneic HSCT and posits that further discussion and perhaps evaluation of this approach for early intervention in certain patients with T1D should be considered. There have been no clinical studies to date evaluating the efficacy of allogeneic HSCT in adult or pediatric T1D patients. Initial studies exploring this approach should focus on risk stratification to identify candidate patients and donors with the highest likelihood of success and lowest risk of complications, and early intervention to preserve remaining beta-cell function.
Reduced-intensity conditioning regimens can minimize transplantrelated risks while maintaining a reasonable probability of donor engraftment.
Given the current success of allogeneic HSCT in curing other nonmalignant conditions in pediatric patients, a prospective clinical trial comparing standard insulin therapy and allogeneic HSCT from an HLA identical sibling donor lacking islet cell antibodies may be warranted to evaluate the merits of this approach. If such a trial showed allogeneic transplant to be a curative option for patients with early onset T1D, it would necessitate that families make the decision of whether to accept the immediate risks and possible late sequelae associated with transplant (e.g. chronic GVHD), compared with the lifestyle alterations and risks of living with a chronic disease requiring insulin therapy (e.g.
hypoglycemia, chronic kidney disease). While these will undoubtedly prove to be difficult decisions for families to consider, the existence of a potentially curative option is generally thought of as a welcome change in the management of an otherwise chronic disease.
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